Subscription-based telehealth provider EZaccessMD announced that it launched a rapid, in-home COVID-19 test from Becton Dickinson (NYSE:BDX).
Rochester, N.Y.-based EZaccessMD said in a news release that its new offering for subscribers brings mobile testing equipment and a qualified provider into the home at no extra charge. The company touts a two-hour response time and test result delivery within 15 minutes.
EZaccessMD will provide a rapid antigen test by Becton Dickinson which it says delivers an overall accuracy of 98%.
If a patient tests positive, the physician will determine the best treatment plan and report all test results to the appropriate authorities. EZaccessMD then provides a three-day follow-up to check on the patient’s progress.
“This unique and convenient testing approach is an absolute game-changer because it allows patients to stay in the comfort of their homes and be treated quickly,” EZaccessMD president Lois Irwin said in the release. “Rapid in-home testing for subscribers is faster and more convenient than any testing option currently available and helps reduces the overall exposure risk to the community.”
“Consumers everywhere are seeking home delivery services, so why not healthcare?” added EZaccessMD CEO Will Irwin. “We have removed the cost and travel barriers that traditional brick and mortar medicine necessitates and wholeheartedly believe this new approach will make a significant difference in the fight against this pandemic.”
